Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer [EXTENSION OF 700194575]

Trial Profile

Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer [EXTENSION OF 700194575]

Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2016

At a glance

  • Drugs OCV 101 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors OncoTherapy Science
  • Most Recent Events

    • 20 Nov 2015 Status changed from active, no longer recruiting to completed, according to University Hospital Medical Information Network - Japan record.
    • 31 May 2013 Status changed from completed to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 16 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top